Peer-reviewedCC BY-NC-NDInternal Medicine
Management of an Allogeneic HSCT Recipient with an SICD during and after Total Body Irradiation
Abstract
A 19-year-old woman with acute myeloid leukemia who had received a subcutaneous implantable cardioverter defibrillator (SICD) was scheduled to undergo allogeneic hematopoietic stem cell transplantation (HSCT). The conditioning regimen included total body irradiation (TBI) at a dose of 12 Gy, under which the SICD was considered at high risk for malfunction. We planned to deactivate and reactivate the SICD before and after each TBI session to mitigate the risk of device malfunction. Additionally, SICD shielding measures were implemented during TBI to minimize the risk of malfunction. Through these procedures, HSCT could be performed without significant adverse events linked to the SICD.
Related
- Routine Pringle Maneuver During Recipient Hepatectomy Is Associated with Improved Perioperative and Early Graft Outcomes After Adult Liver Transplantation
- Addition of thiotepa to total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma: a propensity score-matched retrospective study.
- Diagnostic and Management Challenges in Mixed-Source MDR Sepsis in a Kidney Transplant Recipient with an Infected Sacral Pressure Ulcer Treated with VAC Therapy: A Case Report
- Agonal time in donation after circulatory death lung donors and associations with early recipient pulmonary allograft function and long-term post-transplant outcomes
- Immune-Mediated Demyelinating Central Nervous System Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
BibTeX
@article{matsuoka2026management,
title = {{Management of an Allogeneic HSCT Recipient with an SICD during and after Total Body Irradiation}},
author = {Akari Matsuoka and Shun-Ichi Kimura and Masakatsu Kawamura and Nozomu Yoshino and Masashiro Saeki and Yusuke Ugata and Masato Suzuki and Keiko Akahane and Takuto Ishikawa and Tomohiro Meno and Yuhei Nakamura and Shunto Kawamura and Junko Takeshita and Yukiko Misaki and Kazuki Yoshimura and Ayumi Gomyo and Yosuke Okada and Masaharu Tamaki and Machiko Kusuda and Katsuyuki Shirai and Hideki Nakasone and Shinichi Kako and Yoshinobu Kanda},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.6197-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6197-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Management of an Allogeneic HSCT Recipient with an SICD during and after Total Body Irradiation
AU - Akari Matsuoka
AU - Shun-Ichi Kimura
AU - Masakatsu Kawamura
AU - Nozomu Yoshino
AU - Masashiro Saeki
AU - Yusuke Ugata
AU - Masato Suzuki
AU - Keiko Akahane
AU - Takuto Ishikawa
AU - Tomohiro Meno
AU - Yuhei Nakamura
AU - Shunto Kawamura
AU - Junko Takeshita
AU - Yukiko Misaki
AU - Kazuki Yoshimura
AU - Ayumi Gomyo
AU - Yosuke Okada
AU - Masaharu Tamaki
AU - Machiko Kusuda
AU - Katsuyuki Shirai
AU - Hideki Nakasone
AU - Shinichi Kako
AU - Yoshinobu Kanda
PY - 2026
DA - 2026/09/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6197-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6197-25/_article
AB - A 19-year-old woman with acute myeloid leukemia who had received a subcutaneous implantable cardioverter defibrillator (SICD) was scheduled to undergo allogeneic hematopoietic stem cell transplantation (HSCT). The conditioning regimen included total body irradiation (TBI) at a dose of 12 Gy, under which the SICD was considered at high risk for malfunction. We planned to deactivate and reactivate the SICD before and after each TBI session to mitigate the risk of device malfunction. Additionally, SICD shielding measures were implemented during TBI to minimize the risk of malfunction. Through these procedures, HSCT could be performed without significant adverse events linked to the SICD.
SN - 1349-7235
SN - 0918-2918
ER -